Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors

F. Doz, F. Locatelli, A. Baruchel, N. Blin, B. De Moerloose, D. Frappaz, M. Dworzak, M. Fischer, J. Stary, R. Fuertig, K. Riemann, T. Taube, D. Reinhardt,

. 2019 ; 66 (10) : e27900. [pub] 20190705

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze I, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006187

BACKGROUND: Volasertib induces mitotic arrest and apoptosis by targeting Polo-like kinases. In this phase I dose-escalation study, the maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary efficacy of volasertib were determined in pediatric patients. METHODS: Patients aged 2 to <18 years with relapsed/refractory acute leukemia/advanced solid tumors (ST) without available effective treatments were enrolled-cohort C1 (aged 2 to <12 years); cohort C2 (aged 12 to <18 years). The patients received volasertib intravenously (starting dose: 200 mg/m2 body surface area on day 1, every 14 days). The primary endpoint was the pediatric MTD for further development. RESULTS: Twenty-two patients received treatment (C1: leukemia, n = 4; ST, n = 8; C2: leukemia, n = 3; ST, n = 7). No dose-limiting toxicities (DLTs) occurred up to 300 mg/m2 volasertib in C1; two patients in C2, at 250 mg/m2 volasertib, had DLTs in cycle 1, one of which led to death; therefore, the MTD of volasertib in C2 was 200 mg/m2 . The most common grade 3/4 adverse events (all patients) were febrile neutropenia, thrombocytopenia, and neutropenia (41% each). Stable disease (SD) was the best objective response (leukemia, n = 5; ST, n = 2); the duration of SD was short in all patients, except in one with an ST. PK profiles were generally comparable across dose groups and were consistent with those in adults. CONCLUSION: The pediatric MTD/dose for further development was identified. There were no unexpected safety or PK findings; limited antitumor/antileukemic activity was demonstrated.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006187
003      
CZ-PrNML
005      
20200525153528.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pbc.27900 $2 doi
035    __
$a (PubMed)31276318
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Doz, François $u Oncology Center SIREDO (Care Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institute Curie and University Paris Descartes, Paris, France.
245    10
$a Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors / $c F. Doz, F. Locatelli, A. Baruchel, N. Blin, B. De Moerloose, D. Frappaz, M. Dworzak, M. Fischer, J. Stary, R. Fuertig, K. Riemann, T. Taube, D. Reinhardt,
520    9_
$a BACKGROUND: Volasertib induces mitotic arrest and apoptosis by targeting Polo-like kinases. In this phase I dose-escalation study, the maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary efficacy of volasertib were determined in pediatric patients. METHODS: Patients aged 2 to <18 years with relapsed/refractory acute leukemia/advanced solid tumors (ST) without available effective treatments were enrolled-cohort C1 (aged 2 to <12 years); cohort C2 (aged 12 to <18 years). The patients received volasertib intravenously (starting dose: 200 mg/m2 body surface area on day 1, every 14 days). The primary endpoint was the pediatric MTD for further development. RESULTS: Twenty-two patients received treatment (C1: leukemia, n = 4; ST, n = 8; C2: leukemia, n = 3; ST, n = 7). No dose-limiting toxicities (DLTs) occurred up to 300 mg/m2 volasertib in C1; two patients in C2, at 250 mg/m2 volasertib, had DLTs in cycle 1, one of which led to death; therefore, the MTD of volasertib in C2 was 200 mg/m2 . The most common grade 3/4 adverse events (all patients) were febrile neutropenia, thrombocytopenia, and neutropenia (41% each). Stable disease (SD) was the best objective response (leukemia, n = 5; ST, n = 2); the duration of SD was short in all patients, except in one with an ST. PK profiles were generally comparable across dose groups and were consistent with those in adults. CONCLUSION: The pediatric MTD/dose for further development was identified. There were no unexpected safety or PK findings; limited antitumor/antileukemic activity was demonstrated.
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a leukemie $x farmakoterapie $7 D007938
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a maximální tolerovaná dávka $7 D020714
650    _2
$a nádory $x farmakoterapie $7 D009369
650    _2
$a pteridiny $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D011621
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Locatelli, Franco $u Department of Paediatric Haematology and Oncology, IRCCS (Istituto di Recovero e Cura a Carattere Scientifico), Bambino Gesù Children's Hospital, Sapienza University of Rome, Rome, Italy.
700    1_
$a Baruchel, André $u Department of Paediatric Haemato-immunology, Hôpital Robert Debré (APHP), University Paris Diderot, Paris, France.
700    1_
$a Blin, Nicolas $u Paediatric Haematology and Oncology, Hôpital Mère-Enfant, CHU de Nantes, Nantes, France.
700    1_
$a De Moerloose, Barbara $u Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium.
700    1_
$a Frappaz, Didier $u Paediatric Oncology Department, Léon Bérard Centre, Lyon, France.
700    1_
$a Dworzak, Michael $u St. Anna Children's Hospital, Department of Paediatrics, Medical University of Vienna, Vienna, Austria.
700    1_
$a Fischer, Matthias $u Department of Experimental Paediatric Oncology, University Children's Hospital Cologne, Centre of Molecular Medicine, Medical Faculty, University of Cologne, Cologne, Germany.
700    1_
$a Stary, Jan $u Department of Paediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Fuertig, Rene $u Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
700    1_
$a Riemann, Kathrin $u Clinical Operations, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
700    1_
$a Taube, Tillmann $u Medical Oncology, Boehringer Ingelheim International GmbH, Biberach, Germany.
700    1_
$a Reinhardt, Dirk $u Department of Paediatrics, University Hospital Essen, Essen, Germany.
773    0_
$w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 66, č. 10 (2019), s. e27900
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31276318 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200525153527 $b ABA008
999    __
$a ok $b bmc $g 1525045 $s 1096243
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 66 $c 10 $d e27900 $e 20190705 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace